Moscow’s Pre-Trial Patent Blockade Proposal Hits a Wall
A legislative initiative that would have empowered Russia’s patent office, Rospatent, to block the sale of medicines accused of infringing intellectual property without a court order has met stiff resistance from the Ministry of Health. In a formal review obtained by Kommersant, the ministry argued that the proposal introduces unnecessary administrative hurdles for drug companies and interferes with existing legal protections that already place patent disputes squarely in the judicial domain.
The draft law, developed by the Ministry of Economic Development, envisioned a special commission under Rospatent capable of banning a drug’s digital traceability – effectively freezing its movement and sale – within two months of a rights holder’s complaint. Currently, stopping a copycat medicine usually requires a protracted court battle that can drag on for years. Over 2022–2025, patent-related litigation in the pharmaceutical sector doubled compared to the previous five-year period, with 60 cases launched in the last two years alone.
The Ministry of Health countered that the Civil Code already guarantees patent protection solely through court proceedings and that giving Rospatent access to the medicine tracking system (MDLP) lacks justification. The agency, which normally oversees healthcare compliance, is not a specialized pharmaceutical regulator, the ministry stressed. The Eurasian Economic Union’s Association of Pharmaceutical Manufacturers also condemned the plan, saying it would allow Rospatent to take decisions risky for public health and needed to be either rewritten or scrapped entirely.
Meanwhile, Infarma, the association representing international drug producers, voiced strong support for the mechanism. It argued that manufacturers of innovative, patented medicines routinely fail to stop infringements in time, as copycat versions appear on the market without consent and litigation trails behind. Infarma’s head Vadim Kukava suggested that procedural fine-tuning and amendments to the Civil Code would address concerns, but otherwise backed the faster administrative route.
Why Domestic and International Drugmakers Are on Opposite Sides
A Bureaucratic Power Struggle, Not Just About Patents
At the heart of the clash is a turf war between ministries and regulatory bodies. The Ministry of Economic Development designed the tool to strengthen intellectual property rights, but the Ministry of Health sees it as an encroachment on its own domain – and a potential duplication of the oversight already exercised by Roszdravnadzor, the healthcare watchdog. Granting Rospatent a direct line to stop drug circulation via the digital traceability system would bypass both the health regulator and the courts, concentrating significant power in an agency better known for issuing patents than policing the drug supply chain.
Domestic vs. International Pharma: A Fault Line Widens
The divide between Russian and foreign manufacturers is stark. Domestic firms, often behind the generic versions that would be the immediate targets of such a block, frame the proposal as excessive regulation that could stifle competition and limit patient access to affordable alternatives. International originators, on the other hand, have long complained that Russia’s court-based enforcement is too slow to protect their investments, making an administrative remedy essential. This schism mirrors a broader global debate, but in Russia it is amplified by a domestic industry that has grown rapidly by manufacturing off-patent and near-patent medicines.
What Would Actually Change if the Law Passed
Should the Economic Development Ministry’s plan eventually survive, Rospatent would be able to issue an order to the “Chestny Znak” tracking operator within weeks of a complaint, freezing a disputed drug’s digital passport. The effect would be immediate: no further shipments, no pharmacy sales. A company caught in such a freeze could challenge the decision, but the burden would shift dramatically from the rights holder to the alleged infringer. For now, however, the Health Ministry’s opposition makes swift passage unlikely; the initiative will almost certainly return to the drawing board at the working group hosted by the Agency for Strategic Initiatives.
What This Inter-Ministry Standoff Means for Pharma Companies
For the pharmaceutical sector, the immediate read-out is clear:
- The proposal in its current form is stalled. Companies holding Russian patents should not count on a new fast-track tool and must continue to rely on the court system, which remains slow but is the only enforceable avenue for now.
- Generic manufacturers who have launched products that challenge existing patents will face no administrative blockade; their distribution and sales are secure until a final court ruling appears – a process that can take years.
- Any eventual compromise is likely to require tighter procedural safeguards and explicit amendments to the Civil Code, as even Infarma acknowledges. This means the earliest a new mechanism could be operational is 2027 or later, after a full legislative cycle.
- Monitoring the Agency for Strategic Initiatives’ working group and the Economic Development Ministry’s next draft will be essential, as a revised bill could narrow the scope of Rospatent’s powers or add Health Ministry oversight, reshaping the playing field for both originators and generics.
Risk & Opportunity Assessment
| Commercial Risk | Medium | Patent holders face prolonged revenue erosion as infringing generics can remain on the market for years during court battles, with no administrative brake. A Medium rating reflects the ongoing financial damage even as the proposal stalls. |
| Competitive Risk | Medium | Domestic generic firms gain a prolonged window to build market share in disputed molecules; if a fast-track mechanism later emerges, some of that share could evaporate quickly. The standoff thus keeps current advantages in place for now. |
| Regulatory Risk | High | The direct opposition from the Ministry of Health, a critical gatekeeper for pharmaceutical regulations, sharply reduces the likelihood the bill passes in its original form and raises the prospect of a protracted or entirely abandoned legislative effort. |
| Reputation Risk | Low | The debate is mostly an intra-governmental and industry concern, with limited public visibility. None of the parties involved faces acute reputational damage. |
| Technology Disruption | Low | This is a regulatory process change, not a technology-driven shift. The underlying patent disputes and drug-manufacturing methods remain unchanged. |
| Commercial Opportunity | High | If a revised version of the mechanism eventually passes, original drugmakers would gain a potent new tool to block copycat launches within weeks rather than years, significantly strengthening their exclusivity positions in the Russian market. |
Comments 0